Table 4.

Multivariable Cox regression analyses for mortality in selected therapies

Factors	HR	95% CI	P value
HD-MTX versus no-HD-MTX	0.70	0.53–0.93	0.013
Age
<65	Reference	n.a.	n.a.
65–70	1.12	0.88–1.43	0.367
71–75	1.16	0.89–1.51	0.286
>75	1.30	0.94–1.81	0.113
KPS ≥ 70%	0.51	0.41–0.62	<0.001
HD-MTX + any other CT versus HD-MTX monotherapy	0.54	0.35–0.84	0.006
Age
<65	Reference
65–70	0.91	0.66–1.21	0.502
71–75	0.85	0.62–1.18	0.328
>75	1.08	0.72–1.59	0.711
KPS ≥ 70%	0.49	0.38–0.62	<0.001
HD-MTX + multiagent i.v. CTa versus HD-MTX + oral CT	1.39	0.90–2.15	0.143
Age
<65	Reference
65–70	1.11	0.76–1.64	0.584
71–75	1.23	0.77–1.95	0.389
>75	1.79	1.09–2.93	0.022
KPS ≥ 70%	0.48	0.35–0.66	<0.001

^aHD-MTX plus at least two other i.v. agents (aggressive).

CI, confidence interval; CT, chemotherapy; HD-MTX, high-dose methotrexate; HR, hazard ratio; KPS, Karnofsky performance score; WBRT, whole-brain radiotherapy.